Genfleet Therapeutics (2595 HK): Synthetic Expert Call Transcript (10 Sep 2026)
First-in-Class vs. Best-in-Class Divergence: While Genfleet’s KRAS G12C inhibitor fulzerasib (Dupert®) secured first-to-market status in China in...
88 Views
Aequitas: GenFleet Therapeutics IPO Lockup - Over 50% Is Owned by Pre-IPO Investors, CCASS Movement
Genfleet Therapeutics (2595 HK) (GFT) raised around US$240m in its Hong Kong IPO in September 2025. The lockup on its pre-IPO investors is set to...
108 Views
Genfleet Therapeutics (2595 HK): Synthetic Expert Call Transcript (16 Jul 2026)
Opportunistic Capital Allocation Mitigates Impending R&D Spike: Despite holding RMB 2.07 billion in cash as of December 31, 2025, following...
104 Views
Genfleet Therapeutics (2595 HK) Placement: RAS Portfolio Offerings To Deliver Strength
​Genfleet Therapeutics (2595 HK) announces placement of 13.6M shares at HK$34.69/share, aiming to advance core products, enhance R&D, and expand...
136 Views
Key Takeaways from WCLC 2026: Akeso/SMMT, Hansoh/GSK, MediLink/Roche, RemeGen/AbbVie...
For WCLC 2026 (World Conference on Lung Cancer), we summarise key updates for drugs from Akeso/SMMT, Hansoh/GSK, MediLink/Roche, RemeGen/AbbVie,...
106 Views